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Inhibitor of Apoptosis Proteins as Novel Targets in
Inflammatory Processes
Bettina A. Mayer, Markus Rehberg, Annette Erhardt, Alexander Wolf, Christoph A. Reichel,
Michael Kracht, Fritz Krombach, Gisa Tiegs, Stefan Zahler, Angelika M. Vollmar, Robert Fu¨rst
Objective—Inhibitor of apoptosis proteins (IAPs), such as X-linked or cellular IAP 1/2 (XIAP, cIAP1/2), are important
regulators of apoptosis. IAP antagonists are currently under clinical investigation as anticancer agents. Interestingly,
IAPs participate in the inflammation-associated TNF receptor signaling complex and regulate NFB signaling. This
raises the question about the role of IAPs in inflammation. Here, we investigated the anti-inflammatory potential of IAP
inhibitors and the role of IAPs in inflammatory processes of endothelial cells.
Methods and Results—In mice, the small molecule IAP antagonist A-4.10099.1 (ABT) suppressed antigen-induced
arthritis, leukocyte infiltration in concanavalin A-evoked liver injury, and leukocyte transmigration in the TNF-acti-
vated cremaster muscle. In vitro, we observed an attenuation of leukocyte–endothelial cell interaction by downregu-
lation of the intercellular adhesion molecule-1. ABT did not impair NFB signaling but decreased the TNF-induced
activation of the TGF-–activated kinase 1, p38, and c-Jun N-terminal kinase. These effects are based on the
proteasomal degradation of cIAP1/2 accompanied by an altered ratio of the levels of membrane-localized TNF
receptor-associated factors 2 and 5.
Conclusion—Our results reveal IAP antagonism as a profound anti-inflammatory principle in vivo and highlight IAPs as
important regulators of inflammatory processes in endothelial cells. (Arterioscler Thromb Vasc Biol. 2011;31:2240-2250.)
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X-linked inhibitor of apoptosis protein (XIAP), cellularinhibitor of apoptosis protein-1 (cIAP1) and -2 (cIAP2)
are the best characterized mammalian members of the inhib-
itor of apoptosis protein (IAP) family, whose common feature
is the presence of baculoviral IAP repeat (BIR) domains. The
IAPs, in particular XIAP, have been implicated in the
regulation of cell death by interaction with caspases via their
BIR domains.1,2 Because IAPs are frequently overexpressed
in human malignancies,3,4 they became highly attractive
targets for the development of promising anticancer therapeu-
tics. One strategy to develop IAP-targeting compounds was
based on the structure of the endogenous IAP antagonist
Smac. The peptidic Smac mimetic ABT [compound 11
reported in Oost et al5], which we used as an experimental
IAP inhibitor in this work, is a small molecule inhibitor
modeled to bind to the BIR3 domain of XIAP with a
nanomolar affinity and has successfully been used as an
apoptosis-inducing compound in anticancer strategies.5
See accompanying article on page 2165
In addition to its caspase-inhibiting function, XIAP is
known to interact with NFB and mitogen-activated protein
kinase (MAPK) signaling.6,7 The cIAPs have been reported to
participate in the TNF receptor (TNFR)-associated signaling
complex where they are involved in the ubiquitin-mediated
signaling and in the associated activation of NFB.8–11
Besides TNFR signaling, IAPs were found to be involved in
TRAIL-R, CD40, BAFF-R, and nucleotide-binding and oli-
gomerization domain-containing protein 1/2 signaling.12
Moreover, recent publications indicate a regulatory role of
IAPs in immune functions by controlling cell survival13 or
activation of immune cells. IAPs have been shown to regulate
the cytokine production of macrophages via participating in
the nucleotide-binding and oligomerization domain signal-
ing,14 and Bauler et al15 has identified XIAP as a regulator of
innate immunity to Listeria infections. These findings point
toward a complex role of IAPs in cellular processes beyond
the regulation of apoptosis.
The TNFR signaling is of utmost importance for the
induction of a wide variety of inflammatory processes and
their activation plays a crucial role in the pathogenesis and
progression of many severe disorders, such as atherosclerosis,
arthritis, or sepsis.16 One hallmark of inflammation is the
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extravasation of circulating leukocytes from the blood into
the inflamed tissue. The endothelium tightly regulates and, on
activation by proinflammatory stimuli, such as TNF,
strongly promotes this process and is thus a crucial player in
inflammation.
We inferred from the existing knowledge that IAPs could
be crucial mediators of inflammation and that IAP antago-
nists might thus exert anti-inflammatory actions. Conse-
quently, we analyzed the general capability of IAP inhibition
to influence inflammation in vivo and investigated the under-
lying molecular mechanisms of action in vitro in endothelial
cells (ECs).
Methods
An expanded version of this section can be found in the supplemental
material available at http://atvb.ahajournals.org.
Smac Mimetics
A-4.10099.1 (ABT) [compound 11 reported in Oost et al5] was
kindly provided by Abbott Bioresearch Corporation, Worcester, MA.
The monomeric compound Smac066 [compound 40d reported in
Seneci et al17] and the dimeric Smac085 (unpublished) were kindly
provided by the group of Prof. Pierfausto Seneci (Department of
Organic and Industrial Chemistry, University of Milano,
Milan, Italy).
Animals
All experiments were performed with male C57BL/6 mice (Charles
River, Sulzfeld, Germany) according to the German legislation for
the protection of animals and approved by the local
governmental authorities.
Murine Antigen-Induced Arthritis
The antigen-induced arthritis experiment was performed as previ-
ously described by Veihelmann et al.18 Briefly, mice were immu-
nized against methylated bovine serum albumin (Sigma-Aldrich,
Taufkirchen, Germany) and arthritis was induced by injection of
methylated bovine serum albumin into the left knee joint.
Concanavalin A-Induced Murine Hepatitis
The model has been described previously in detail.19 Briefly,
concanavalin A (ConA; Sigma-Aldrich) was administered to mice
intravenously at 15 mg/kg. One g ABT was administered intrave-
nously 15 minutes before ConA. Mice were euthanized 8 hours after
ConA application. Plasma enzyme activity of alanine aminotransferase
was assessed using an automated procedure with COBAS MIRA
(Roche, Basel, Switzerland). Liver tissue paraffin sections were stained
with a naphthol-AS-D-chloroacetate-esterase kit (Sigma-Aldrich).
Analysis of Leukocyte Adhesion and
Transmigration by Intravital Microscopy of the
Mouse Cremaster Muscle
The surgical preparation of the cremaster muscle and the intravital
microscopy were performed as described by Baez.20
Cell Culture and Media
Primary human umbilical vein endothelial cells (HUVECs) were
isolated from umbilical cords. HUVECs and HeLa cells were
cultured as previously described.21,22 Human neutrophil granulocytes
were separated from heparinized peripheral blood of healthy volun-
teers by using CD15 MicroBeads (Miltenyi, Bergisch Gladbach,
Germany).
Granulocyte Adhesion Assay
Neutrophil granulocytes were added to confluent HUVECs that were
pretreated or not with CD54 blocking antibody/isotype control
(Biolegend, San Diego, CA) and allowed to adhere for 30 minutes.
After lysis, the amount of adhered granulocytes was analyzed by
measurement of myeloperoxidase activity.
Flowcytometric Analysis
Oxidative Burst
Neutrophils were primed with dihydrorhodamine (1 mol/L) for 10
minutes.
CD11b Surface Expression
Granulocytes were incubated with a FITC-labeled anti-CD11b anti-
body (AbD Serotec, Du¨sseldorf, Germany).
ICAM-1 Expression
HUVECs were trypsinized, formalin-fixed, and incubated with a
FITC-labeled anti-CD54 antibody (Biozol, Eching, Germany). Cells
were analyzed with a FACSCanto II flow cytometer (Becton
Dickinson, Heidelberg, Germany).
ICAM-1 and Interleukin-8 mRNA Expression
HeLa cells were treated as indicated and ICAM-1/interleukin-8
mRNA expression was measured by real-time RT-PCR as previously
described.23
Quantification of Cell Death
Apoptosis rates were measured by determination of subdiploid DNA
content as previously described.24 Briefly, permeabilized cells were
stained with propidium iodide and analyzed by flow cytometry on a
FACSCalibur (Becton Dickinson). General cell death rates were
quantified by staining nonpermeabilized cells with propidium iodide
and subsequently analyzing the propidium iodide positive cells by
flow cytometry.
Western Blot Analysis
Proteins were separated by SDS-PAGE and transferred to nitrocel-
lulose membranes (GE Healthcare, Munich, Germany) via electro-
blotting. The following antibodies were used: Phospho-TGF-–ac-
tivated kinase 1 (TAK1), phospho-extracellular signal-regulated
kinase, TNF receptor-associated factor 2 (TRAF2), phospho-p38,
phospho-cJun N-terminal kinase (JNK), phospho-IB, ubiquitin,
and receptor-interacting protein1 (RIP1; Cell Signaling/NEB, Frank-
furt am Main, Germany). MAPK phosphatase-1, IB, p52 (NFB),
TRAF5 (Santa Cruz, Heidelberg, Germany), cIAP1 (R&D Systems,
Wiesbaden, Germany), cIAP2 (Epitomics/Biomol, Hamburg, Ger-
many), and XIAP (Becton Dickinson). Jurkat cell lysate was from
Cell Signaling/NEB.
Analysis of NF-B p65 Intracellular Localization
Formalin-fixed HUVECs were incubated with an anti-NFB p65
(Santa Cruz) primary and AlexaFluor 488-linked secondary antibody
(Molecular Probes, Eugene, OR). The translocation of NFB p65
was analyzed using a Zeiss LSM 510 Meta confocal laser scanning
microscope (Zeiss, Oberkochen, Germany).
Electrophoretic Mobility Shift Assay
Nuclear protein extracts were prepared from HUVECs and electro-
phoretic mobility shift assay was performed as previously
described.25
Dual Luciferase Reporter Assay
Firefly luciferase reporter vector pGL4.32[luc2P/NF-B-RE/Hygro]
and Renilla luciferase reporter vector pGL4.74[hRluc/TK] were from
Promega (Heidelberg, Germany). HUVECs were transfected using
the Amaxa HUVEC Nucleofactor Kit (Lonza, Cologne, Germany).
Luciferase activity was determined using the Dual Luciferase Re-
porter Assay System (Promega).
Mayer et al Inhibitor of Apoptosis Proteins in Inflammation 2241
 at Universitaetsbibliothek LMU on January 23, 2013http://atvb.ahajournals.org/Downloaded from 
Immunoprecipitation
HUVEC lysates were incubated with cIAP1 (R&D Systems) or RIP1
(Cell Signaling) antibody. Proteins were precipitated by adding
Protein A agarose beads (Sigma-Aldrich). Proteins were extracted
from the beads with Laemmli sample buffer and subjected to
Western blot analysis.
TAK1 Kinase Assay
Active TAK1 kinase was precipitated from cell lysates with TAK1
antibody (Cell Signaling). [-32P]ATP and the TAK1 substrate
MAPK kinase 3 (Biaffin, Kassel, Germany) were added to start the
kinase reaction. Samples were analyzed by SDS gel electrophoresis
and phosphorylated MAPK kinase 3 was detected by
autoradiography.
Gene Silencing
HUVECs were transfected with XIAP siRNA (ON-TARGETplus
SMARTpool siRNA), cIAP1 siRNA (ON-TARGETplus duplex
siRNA), cIAP2 siRNA (ON-TARGETplus duplex siRNA) (Thermo
Scientific/Dharmacon, Bonn, Germany), or with the corresponding
nontargeting siRNA by electroporation using the Amaxa HUVEC
Nucleofector kit (Amaxa/Lonza).
Cytosol/Membrane Fractionation
Confluent HUVECs were treated as indicated, lysed, and separated
into a soluble (cytosolic) and a particulate (membranous) fraction, as
described previously by Li et al.26
Statistical Analysis
Bar graph data represent meansSEM. Statistical analysis was
performed with the GraphPad Prism software version 3.03 (Graph-
Pad Software, San Diego, CA). Unpaired t test was used to compare
2 groups. To compare 3 or more groups, 1-way ANOVA followed by
Bonferroni posthoc test was used. P0.05 was considered as
statistically significant.
Results
The IAP Inhibitor ABT Exhibits
Anti-Inflammatory Actions in Murine Models of
Inflammation and Blocks Leukocyte Extravasation
The overall anti-inflammatory potential of ABT was tested in
2 different animal models of inflammation: (1) In the antigen-
induced arthritis model, mice that were treated intraperitone-
ally with 5 g ABT per day did not evolve any joint swelling
in the antigen-treated knee (Figure 1A). (2) In the ConA-
evoked hepatitis model, ABT (1 g, IV) diminished (40%)
the rise in the serum levels of alanine aminotransferase, a
marker for liver cell injury (Figure 1B). Moreover, the
ConA-provoked neutrophil recruitment to the liver, which
crucially contributes to the liver injury, is reduced signifi-
cantly when mice were treated with ABT as shown in
histological images and by determining the neutrophil count
(Figure 1C).
In postcapillary venules of the TNF-treated mouse cre-
master muscle, ABT affected leukocyte extravasation: The
group of mice that was pretreated with 5 g ABT (IA) for 30
minutes showed a slight (nonsignificant) reduction of leuko-
cyte adhesion (20%) and a strong decrease of leukocyte
transmigration (60%) in comparison to the control group
(Figure 1C). Leukocyte rolling, vessel diameter, blood flow
velocity, wall shear rate, and systemic count of leukocytes
were not influenced by ABT (data not shown).
IAP Inhibition Influences Leukocyte Adhesion to
Endothelial Cells and Reduces TNF-Induced
ICAM-1 Expression
Aiming at mechanistic analyses, we confirmed the attenua-
tion of leukocyte–EC interaction in vitro. The adherence of
Figure 1. Antagonist A-4.10099.1 (ABT) protects against
antigen-induced arthritis, diminishes ConA-induced liver injury,
and attenuates leukocyte extravasation in mice. A, Mice were
immunized with methylated BSA (mBSA). One group was addi-
tionally treated IP with 5 g ABT every day beginning 2 days
before the induction of the arthritis with mBSA in the left knee
joint. The right knee joints were injected with NaCl solution
(internal controls). The knee joint diameter was determined daily.
Control mice: N5. ABT-treated mice: N6. *P0.05 vs
ABTmBSA. B, C, Mice were treated IV with 1 g ABT 15 min-
utes before IV administration of 15 mg/kg ConA. Liver tissues
were removed 8 hours after ConA application. ConA-treated
mice: N12. ConAABT-treated mice: N12. B, Plasma levels
of alanine transaminase (ALT) were assessed. C, Liver sections
were stained for naphthol-AS-D-chloroacetate esterase to ana-
lyze neutrophil infiltration. Left: the bar graph shows the quanti-
fication of the neutrophil count in the liver sections. *P0.05 vs
ConA. Right: representative images. Black bar100 m. D, Leu-
kocyte recruitment to the mouse cremaster muscle was induced
by intrascrotal injection of TNF (500 ng) 4 hours before intravi-
tal microscopy. Five micrograms of ABT was injected IA 30 min-
utes before application of TNF. During a 15-minute observation
period, leukocyte adhesion and transmigration were assessed.
TNF-treated mice: N5. ABTTNF-treated mice: N5.
*P0.05 vs TNF.
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freshly isolated human neutrophils to the EC monolayer was
concentration-dependently reduced with an IC50 value of
10 nmol/L (Figure 2A). Pretreatment of ECs with ABT
resulted in a profound concentration-dependent downregula-
tion of endothelial ICAM-1 surface protein expression with
an IC50 value of 18 nmol/L (Figure 2B). An ICAM-1-
blocking antibody strongly reduced the adhesion of neutro-
phils to ECs, thus corroborating the essential role of ICAM-1
for neutrophil adhesion (Figure 2C). Moreover, ABT influ-
ences mRNA levels of both ICAM-1 (Figure 2D) and
interleukin-8 (Figure 2E), as shown in HeLa cells. Regarding
actions of ABT on neutrophils, ABT had no influence on the
formyl-methionyl-leucyl-phenylalanine-induced production
of reactive oxygen species (Figure 2F) and slightly reduced
the expression of CD11b (Figure 2G). These findings indicate
that ABT, besides strongly acting on ECs, might also affect
neutrophil activation.
The Effect of ABT on ICAM-1 Expression Can Be
Mimicked by Structurally Different IAP Inhibitors
and Is Not Due to Increased Apoptosis or
Caspase Activation
Two IAP antagonists structurally different from ABT, the
monomeric Smac mimetic Smac066 and the homodimeric
Smac085, effectively reduced the TNF-evoked ICAM-1
expression (Figure 3A), suggesting that the action of ABT is
not a specific feature of this individual compound due to side
or off-target effects. As assessed by measuring the rate of
apoptosis (subdiploid DNA content), ABT treatment for 24
and 48 hours did not cause any induction of apoptosis (Figure
Figure 2. Influence of antagonist A-4.10099.1 (ABT) on TNF-induced leukocyte–endothelial cell interaction as well as on TNF-acti-
vated pathways in endothelial cells, HeLa cells, and leukocytes. Human umbilical vein endothelial cells (HUVECs) were preincubated for
30 minutes with ABT (A) or with intercellular adhesion molecule-1 (ICAM-1) blocking antibody (CD54, 20 g) for 1 hour (C) and treated
with TNF (10 ng/mL) for 24 hours. Isolated human neutrophil granulocytes were added (105 cells per well) and allowed to adhere for
45 minutes. Myeloperoxidase activity kinetics were measured to determine the amount of adhered granulocytes. A, N7. *P0.05 vs
TNF alone. B, HUVECs were pretreated with ABT for 30 minutes and treated with TNF (10 ng/mL) for 24 hours. The levels of ICAM-1
surface expression were determined by flow cytometry. N3. C, N3. *P0.05 vs TNF alone. D, E, HeLa cells were treated with ABT
(1 mol/L) for 30 minutes. TNF (20 ng/mL) was applied for 3 hours. ICAM-1 (D; N3) and IL-8 (E; N5) mRNA expression were ana-
lyzed by real-time RT-PCR. *P0.05 vs TNF alone. F, G, Isolated human neutrophil granulocytes were treated for 30 minutes with
ABT before incubation with 100 nmol/L fMLP for 15 minutes. F, Granulocytes were loaded with 10 mol/L dihydrorhodamine and ana-
lyzed by flow cytometry. N3. G, CD11b surface expression was measured by flow cytometry. N3. *P0.05 vs fMLP alone.
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3B, left and middle panel). Even the additional presence of
TNF for 24 hours did not evoke apoptotic cell death (Figure
3B, right panel). Moreover, by quantification of propidium
iodide-positive cells after 24 and 48 hours of treatment with
ABT and TNF (Figure 3C), we revealed that the IAP
antagonist does not trigger cell death in HUVECs. Thus, it
can be excluded that the effects of ABT on ECs are simply
due apoptosis induction. Furthermore, it can also be excluded
that caspases participate in the action of ABT on the TNF-
induced ICAM-1 expression: Figure 3D shows that the
application of a pan-caspase inhibitor (Q-VD-OPh) had no
impact on this effect.
ABT Does Not Interfere With the Endothelial
NFB Signaling
NFB is the major transcription factor that regulates ICAM-1
expression; however, as shown in Figure 4A, ABT did neither
influence the phosphorylation of the NFB inhibitor IB,
nor its degradation evoked by TNF. Also, both the TNF-
induced translocation of the NFB subunit p65 to the nucleus
(Figure 4B) and the DNA-binding capacity of NFB were left
unaffected by ABT (Figure 4C). Besides this canonical way
of NFB activation, ABT treatment did also not lead to an
induction of the noncanonical NFB signaling, because
neither ABT alone nor in combination with TNF did evoke
the processing of p100 to p52 (Figure 4D). Finally, the
TNF-evoked NFB-dependent gene expression was not
affected by ABT in a dual-luciferase reporter gene assay
(Figure 4E, left). Curcumin, which is known to inhibit NFB
signaling by blocking IB phosphorylation,27 was used as a
positive control (Figure 4E, right).
IAP Inhibition Affects Endothelial
MAPK Signaling
Figure 5A shows that ABT diminished the TNF-induced
phosphorylation of the MAPKs p38 and JNK, but not of
extracellular signal-regulated kinase, and did not affect the
protein levels of the MAPK phosphatase-1. Pharmacological
inhibition of p38 and JNK resulted in a significant decrease of
TNF-induced ICAM-1 expression (Figure 5B). The added
levels of ICAM-1 reduction caused by the 2 inhibitors
SP600125 (JNK) and SB203580 (p38) nicely correspond to
the level caused by ABT. In addition, ABT affects the p38-
and JNK-activating MAP3K TAK1: The TNF-induced
phosphorylation of TAK1, indicating its activation, was
reduced when cells were pretreated with the IAP antagonist
(Figure 5C). Moreover, by performing a TAK1 kinase assay
that uses MAPK kinase 3 as a TAK1 substrate, we could
confirm the inhibitory action of ABT treatment on the
TNF-triggered TAK1 activity (Figure 5D). Taken together,
ABT inhibited the TNF-induced activation of p38, JNK, and
TAK1.
Targeting of cIAP1 and cIAP2, But Not of XIAP,
Accounts for the ICAM-1-Reducing Effect of ABT
We tested whether gene silencing of XIAP, cIAP1, or cIAP2
results in similar effects on ICAM-1 expression as treating
ECs with the IAP antagonist. Surprisingly, a reduction of
endothelial XIAP levels on transfection of siRNA resulted in
Figure 3. The effect of antagonist A-4.10099.1 (ABT) on intercellular adhesion molecule-1 (ICAM-1) expression can be mimicked by
structurally different inhibitor of apoptosis protein (IAP) inhibitors and is not due to increased apoptosis or caspase activation. A,
Human umbilical vein endothelial cells (HUVECs) were treated with Smac066 (monovalent) or Smac085 (bivalent) for 30 minutes before
incubation with TNF (10 ng/mL) for 24 hours. The levels of ICAM-1 surface protein expression were determined by flow cytometry.
N3. *P0.05 vs TNF alone. B, HUVECs were treated with ABT for 24 or 48 hours or they were pretreated with ABT for 30 minutes
before incubation with TNF (10 ng/mL) for 24 hours. Subdiploid DNA content was determined by flow cytometry. N3. C, HUVECs
were pretreated for 30 minutes with ABT and subsequently treated with TNF (10 ng/mL) for 24 or 48 hours. Cells were then incubated
with propidium iodide (PI; 10 g/mL) for 30 minutes. PI positive cells were analyzed by flow cytometry. Cells permeabilized with Triton
X-100 (0.1%) were used as a positive control. N3. D, HUVECs were pretreated with the pan-caspase inhibitor Q-VD-OPh (10 mol/L,
30 minutes) before treatment with ABT (100 nmol/L) for 30 minutes and TNF (10 ng/mL) for 24 hours. The levels of ICAM-1 surface
protein expression were determined by flow cytometry. N3. *P0.05 vs TNF alone.
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a huge increase of ICAM-1 expression and ABT was still
capable of reducing ICAM-1 levels (Figure 5E, left). Inter-
estingly, these cells exhibited strongly increased protein
levels of cIAP1 and cIAP2 (Figure 5E, right). Nevertheless,
silencing of cIAP1, cIAP2, and of both significantly reduced
TNF-induced ICAM-1 expression (Figure 5F). Of note, the
degree of reduction is similar to that achievable with ABT.
These results suggest that the presence of XIAP is not
required for the effects of the IAP antagonist and that cIAP1
and cIAP2 are involved in the regulation of TNF-induced
ICAM-1 expression.
ABT Interferes With the TNF Receptor
Proximal Signaling
The fact that silencing of cIAP1 and cIAP2, but not of XIAP,
reduced ICAM-1 expression gave rise to the question in
which way the Smac mimetic influences the activation of p38
and JNK. We analyzed the action of ABT on the protein
levels of XIAP, cIAP1, and cIAP2 and found a rapid and
sustained reduction of cIAP1, whereas XIAP levels were not
affected (Figure 6A). Protein levels of cIAP2 and their
reduction by ABT could only be detected when its expression
was induced by TNF for a longer period of time (24 hours)
as shown in Figure 6C. Furthermore, we could demonstrate
that the IAP antagonist leads to a fast and strong ubiquitina-
tion of cIAP1 (Figure 6B). The pharmacological proteasome
inhibitor MG132 abolished the ABT-evoked disappearance
of cIAP1 and cIAP2 (Figure 6C) and, most importantly,
abrogated the effects of ABT on the TNF-induced expres-
sion of ICAM-1 (Figure 6D), indicating that proteasomal
degradation is important for these events.
cIAP1 and cIAP2 have been described as members of the
TNFR signaling complex.28 We hypothesized that the degra-
dation of cIAP1/2 mediated by ABT influences this complex.
TRAF2 is known to mediate the activation of NFB and
MAP3K signaling29 and was reported to interact with cIAP1/
2.30 ABT triggers an immediate decrease of TRAF2 protein
levels in endothelial membrane fractions (Figure 6E). In
contrast, TRAF5, which can compensate the loss of TRAF2
in terms of activation of the NFB signaling,31,32 was not
affected by ABT (Figure 6E).
Moreover, as shown in Figure 6F, the IAP antagonist led to
a reduced ubiquitination of the TNF receptor-associated
kinase RIP1, which is known to be essential for the TNF-
mediated activation of TAK1.9
In summary, our data indicate that ABT induces the
ubiquitination and proteasomal degradation of cIAP1/2,
which is accompanied by an altered ratio of the levels of
TRAF2 and TRAF5 at the EC membrane and by an altered
ubiquitination status of the TAK1 activator RIP1.
Discussion
Activation of inflammatory processes is crucial for the host
defense against infections and for repairing tissue damage,
but it shows destructive properties in chronic pathological
conditions like atherosclerosis, rheumatoid arthritis, or ische-
mia. The administration of conventional anti-inflammatory
therapeutics, such as glucocorticoids or nonsteroidal anti-
inflammatory drugs, is not always effective and often causes
severe side effects. Consequently, inflammation is still a very
important subject of research in terms of unraveling novel
signaling interconnections in order to develop new therapeu-
tical strategies. IAPs have been increasingly recognized to
affect NFB signaling6 and to be part of the TNF receptor-
Figure 4. Antagonist A-4.10099.1 (ABT) does not interfere with
the endothelial NFB signaling. A, D, HUVECs were pretreated
with ABT (100 nmol/L) for 30 minutes and subsequently treated
with TNF (10 ng/mL). Levels of IB, phospho-IB, and actin
(A) or levels of p100, p52, and actin (D) were determined by
Western blotting. Jurkat lysates were used as positive control
(D). One representative out of 3 independently performed exper-
iments is shown, each. B, NFB p65 subunit was visualized via
immunocytochemistry. White bar40 m. One representative
out of 3 independently performed experiments is shown, each.
C, NFB DNA-binding activity was measured by electrophoretic
mobility shift assay. One representative out of 3 independently
performed experiments is shown, each. E, TNF was applied
for 6 hours. The well-known NFB inhibitor curcumin (curc,
20 mol/L, 30 minutes pretreatment) served as positive control.
NFB promotor activity was analyzed by dual luciferase reporter
gene assay. N3. *P0.05 vs TNF.
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Figure 5. IAP inhibition affects endothelial mitogen-activated protein kinases (MAPK) signaling and silencing of cellular inhibitor of apo-
ptosis protein 1/2 (cIAP1/2), but not of X-linked inhibitor of apoptosis protein (XIAP), inhibits intercellular adhesion molecule-1 (ICAM-1)
expression. A, Human umbilical vein endothelial cells (HUVECs) were treated with 100 nmol/L ABT for 30 minutes before incubation
with 10 ng/mL TNF. Levels of phospho-p38 mitogen-activated protein kinase (MAPK), phospho-c-Jun N-terminal kinase (JNK),
phospho-extracellular signal-regulated kinase (ERK), MAPK phosphatase-1 (MKP-1), and actin were analyzed by Western blotting. One
representative out of 3 independently performed experiments is shown, each. B, HUVECs were treated with ABT (100 nmol/L), the p38
MAPK inhibitor SB203580 (20 mol/L), and the JNK inhibitor SP600125 (10 mol/L) for 30 minutes followed by TNF (10 ng/mL) for 24
hours. Levels of ICAM-1 surface expression were determined by flow cytometry. N3. *P0.05 vs TNF alone. C, D, HUVECs were
pretreated with ABT for 30 minutes followed by 5 minutes TNF (10 ng/mL) treatment. Levels of phospho-TGF-–activated kinase 1
(TAK1) and actin were determined by Western blotting (C). TAK1 was precipitated from cell lysates and, after performing a TAK1 kinase
activity assay, levels of the phosphorylated TAK1 substrate MAPK kinase 3 were detected by autoradiography on gel electrophoresis
(D). One representative out of 3 independently performed experiments is shown, each. E, F, HUVECs were transfected with nontarget-
ing (nt) or specific siRNA against cIAP1, cIAP2, and XIAP. Cells were then treated with ABT (100 nmol/L, 30 minutes) and TNF (10
ng/mL, 24 hours). Levels of ICAM-1 surface expression were determined by flow cytometry. N3. Levels of X-linked inhibitor of apo-
ptosis protein (XIAP), cIAP1, cIAP2, and actin were analyzed by Western blotting. One representative out of 3 independently performed
experiments is shown, each. *P0.05 vs TNF alone.
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associated complex.8,30 Besides their role in the regulation of
cell survival, there is upcoming evidence that the IAPs are
also involved in the regulation of immune functions.12 In the
present work, we demonstrate that IAP inhibitors could open
a new and promising anti-inflammatory approach.
In vivo, the IAP antagonist exerted a profound anti-
inflammatory effect in an antigen-induced arthritis model
and, moreover, inhibited liver injury and leukocyte infiltra-
tion in a ConA-evoked hepatitis model in mice. Also
leukocyte-EC interactions were significantly attenuated in
vivo. The dosing of ABT used in the in vivo models was
deduced from the concentrations that caused both the maxi-
mum inhibition of ICAM-1 expression and a significant
inhibition of leukocyte adhesion in vitro (1 mol/L). In the
arthritis model, ABT was applied IP at 250 g/kg/d. Based on
the theoretical assumption of an immediate and complete
absorption, this dosage could generate a maximum plasma
level of 10 mol/L. Regarding the administration of 50 g/kg
ABT directly into the circulation in the hepatitis and cremas-
ter model, a maximum ABT plasma level of 2 mol/L could
be achieved. Noteworthy, subcutaneously applied doses of up
to 40 mg/kg/d ABT are tolerable in mice.5
Until now, IAP antagonists have only been applied in vivo
to proof them as promising candidates for anticancer therapy:
ABT was successfully used in a murine breast cancer xeno-
graft tumor model5 and, noteworthy, some Smac mimetics
have already entered phase I clinical trials.33 Our work,
however, is the first study that investigates the ant-
inflammatory action of an IAP antagonist in the context of
leukocyte–EC interaction, both in vivo and in vitro. On the
basis of the profound in vivo actions of ABT, we used this
compound as a tool to uncover the role of IAPs in inflam-
matory processes of ECs.
The up-regulation of EC adhesion molecule expression is a
hallmark of inflammatory processes. Endothelial cell adhe-
sion molecules are crucial for leukocyte recruitment to sites
of inflammation and they tightly regulate the different stages
of rolling, adhesion, and transmigration (diapedesis) of leu-
Figure 6. Antagonist A-4.10099.1 (ABT) interacts with the TNF receptor signaling. A, Human umbilical vein endothelial cells (HUVECs)
were treated with ABT (100 nmol/L). Levels of cellular inhibitor of apoptosis protein 1 (cIAP1), X-linked inhibitor of apoptosis protein
(XIAP), and actin were analyzed by Western blotting. One representative out of 3 independently performed experiments is shown. B,
After 30 minutes pretreatment of HUVECs with ABT (100 nmol/L) and subsequent treatment with TNF (10 ng/mL), levels of cIAP1
were analyzed by Western blot (upper panel). Additionally, cIAP1 was precipitated from cell lysates of HUVECs that were pretreated
with the proteasome inhibitor MG132 (10 mol/L, 30 minutes) before treatment with ABT and TNF. Levels of ubiquitinated (Ub) cIAP1
and of precipitated cIAP1 were determined by Western blotting (middle and lower panel). One representative out of 3 independently
performed experiments is shown, each. C, D, HUVECs were pretreated with the proteasome inhibitor MG132 (10 mol/L, 30 minutes)
before treatment with ABT (1 mol/L) for 30 minutes and TNF (10 ng/mL) for 24 hours. The levels of cIAP1, cIAP2, XIAP, and actin
were determined by Western blotting. One representative out of 3 independently performed experiments is shown, each (C). Levels of
ICAM-1 surface expression were determined by flow cytometry. N3. D, E, HUVECs were treated with ABT (1 mol/L, 30 minutes)
followed by TNF (10 ng/mL) for 5 minutes. Cells were then fractionated into cytosol and membrane fractions. The levels of TNF
receptor-associated factors 2 and 5, cIAP1, and actin were determined by Western blotting. One representative out of 3 independently
performed experiments is shown, each. F, Cells were treated with ABT for 30 minutes (100 nmol/L) and subsequently incubated with
TNF (10 ng/mL). Receptor-interacting protein1 (RIP1) was precipitated from cell lysates and levels of ubiquitinated and precipitated
RIP1 were analyzed by Western blotting. One representative out of 3 independently performed experiments is shown.
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kocytes.34 We infer from our data that the IAP antagonist
impairs leukocyte adhesion by inhibiting the expression of
ICAM-1 on ECs, because blocking of ICAM-1 on the EC
surface by a neutralizing antibody clearly lowered leukocyte
adhesion.
Interestingly, the activation of the canonical NFB path-
way, which plays a pivotal role in the upregulation of
ICAM-1, is not targeted by ABT. ABT did also not alter the
noncanonical NFB signaling. This is in contrast to studies
showing that IAP antagonists can activate this signaling
pathway in other cell types.35,36 Instead, ABT inhibited the
activation of the MAPKs p38 and JNK, which have been
reported to regulate cell adhesion molecules37 by activation of
different transcription factors.38 The fact that inhibitors of
JNK and p38 significantly reduce TNF-triggered ICAM-1
expression in ECs suggests that ABT blocks cell adhesion
molecule expression predominantly via an inhibition of these
2 MAP kinases but not via affecting NFB signaling.
The IAP-antagonist ABT, which was modeled to bind to the
BIR3 domain of XIAP, reduced the phosphorylation of the
MAP3K TAK1 (upstream of JNK and p38). However, silenc-
ing of XIAP did not result in an anti-inflammatory effect, but
it even amplified TNF-induced ICAM-1 expression and
caused an increase in the levels of cIAP1 and cIAP2. This
compensatory upregulation of cIAP1 and cIAP2 has also
been reported in XIAP knockout mice.39 In contrast, the
reduction of cIAP1 and/or cIAP2 levels by RNAi led to an
inhibition of the TNF-induced ICAM-1 that is comparable to
the degree of inhibition caused by ABT. Correspondingly, the
IAP antagonist itself evoked a decrease of cIAP1 and cIAP2,
but not of XIAP levels in ECs. Monovalent Smac mimetics,
such as ABT or Smac066, were designed to mimic the Smac
AVPI-binding motif to target the BIR3 domain of XIAP.
Nevertheless, it has been shown that this kind of mimetics
also exhibit high affinities to the BIR3 domains of cIAP1 and
cIAP2.41 Interaction of Smac mimetics with cIAPs influences
their E3-ligase and auto-ubiquitination activity and results in
proteasomal degradation of cIAP1/2, whereas XIAP levels
are not affected.35,36,39–41 We could demonstrate that ABT
induces ubiquitination of cIAP1, which goes along with the
loss of this protein. The exact mode of action of Smac
mimetics in this context has not been elucidated yet. How-
ever, Darding et al42 suggested that Smac mimetic-induced
auto-ubiquitination of cIAPs requires TRAF2 as scaffolding
protein to mediate dimerization of the cIAP RING domain,
which supports their E3-ligase activity. Our findings suggest
that the anti-inflammatory effect of ABT does not arise from
antagonizing XIAP but is connected to the proteasomal
degradation of cIAP1 and cIAP2, which is nicely reflected in
the results of the cIAP1/2 silencing experiments. Interest-
ingly, cIAP1 and cIAP2 knockout mice are asymptomatic,
which might be due to the observed mutual upregulation due
to compensatory mechanisms.13,43 Unfortunately, a cIAP1/2
double knockout mouse, in which the effects of ABT might
be mimicked, is not available. However, the importance of
influencing cIAP1/2 levels for the anti-inflammatory action
of the IAP antagonist is affirmed by our finding that upregu-
lation of cIAP1 and cIAP2 levels in response to XIAP
silencing strongly increases endothelial activation.
Moreover, we found that the reduction of cIAP1 and cIAP2
protein levels influences TNFR signaling and, as a conse-
quence, the activation of the MAP3K TAK1. The TNF-
induced activation of TNFR involves the assembly of the
so-called TNFR-associated complex resulting in an activation
of NFB and MAPK signaling. The recruitment of TRADD
and TRAF2, cIAP1/2 and RIP,29 as well as the degradative
and nondegradative ubiquitination processes exerted by the
E3 ligase function of TRAF2 and cIAP1/2 provide platforms
for the recruitment and activation of the IB kinase and the
TAB/TAK complex.28 cIAP1/2 can directly interact with the
adaptor protein TRAF2 and with RIP1,9,30 which function
both in NFB and MAPK signaling.35,44–46 It has been
reported that the auto-ubiquitination–dependent degradation
of cIAP1 and cIAP2 induced by IAP antagonists completely
abrogates NFB signaling.10,11 In contrast, it has also been
described that cIAP1/2 degradation evoked by a Smac mi-
metic is able to stimulate NFB signaling.36,47 In our setting,
the treatment of ECs with an IAP antagonist resulted in a
proteasome-dependent degradation of cIAP1 and cIAP2 but
not in an alteration of NFB activation. Instead, we detected
a loss of TRAF2 in the EC membrane fraction mediated by
ABT suggesting that the degradation of cIAP1/2 influences
the TNF-induced MAPK activation by affecting TRAF2 in
the TNFR-associated signaling complex. However, there was
no TNF-evoked increase of TRAF2 in the membrane
fractions, as it could have been expected, but nevertheless our
finding is in accordance with the study of Yeh et al reporting
that a loss of TRAF2 prevents TNF-caused activation of
JNK.32 Moreover, we found a reduction of RIP1 ubiquitina-
tion in ABT-treated ECs. Bertrand et al9 showed that cIAP1/2
can directly ubiquitinate RIP1 and that TRAF2 needs to be
present for proper ubiquitination of RIP1. In the absence of
the cIAPs, the association of RIP1 with TAK1 was impaired,
which affected TAK1 signaling. Because TAK1 not only
accounts for an activation of MAPK, but also of IB kinase
and thus NFB,48 the question arises of how MAPK signaling
is impaired by ABT, whereas NFB signaling remains
unaffected. In contrast to TRAF2, the level of TRAF5 in
membrane fraction did not change. In knock-out mice,
TRAF5 has been found to compensate for the absence of
TRAF2 concerning the activation of NFB, but not in regard
to the activation of the MAPK signaling.31,32 This strongly
supports our hypothesis that the degradation of cIAP1 and
cIAP2 in the TNFR-associated signaling complex goes along
with an impaired initiation of MAPK signaling. Thus, the
inflammatory activation of ECs is abrogated, whereas NFB
signaling is not impaired. This may explain why HUVECs
did not die on treatment with ABT and TNF as it has been
described for cancer cells36: The unaffected, ongoing NFB
activation still can mediate a prosurvival signaling.
Inflammation and the regulation of cell death are often
closely connected, not only in the development and progres-
sion of cancer, but also in pathologies like atherosclerosis.49
For example, Moran and Agrawal showed an upregulation of
IAPs in atherosclerotic plaques of patients with carotid
stenosis.50 Therefore, it could be speculated that targeting
IAPs might possess the potential to dually influence inflam-
matory diseases like atherosclerosis, ie, by suppressing in-
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flammatory endothelial signaling processes as well as induc-
ing apoptosis of proliferating vascular smooth muscle cells
and infiltrating immune cells. Most interestingly, Tseng et
al51 describes elimination of cIAPs in macrophages as a
highly specific tool to inhibit proinflammatory genes without
affecting the anti-inflammatory and tumor suppressive IFN
response and suggests IAP antagonists as potentially prom-
ising anti-inflammatory drugs.
In summary, our study provides for the first time evidence
that IAP-inhibiting compounds possess profound anti-
inflammatory properties in vivo. Moreover, we could show
that IAPs play an important regulatory role in the inflamma-
tory activation of ECs and, most importantly, that this might
open a novel therapeutic strategy for the treatment of
inflammation-associated diseases.
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